Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) (PANOBIDARA)

This study has been completed.
Sponsor:
Information provided by:
PETHEMA Foundation
ClinicalTrials.gov Identifier:
NCT00840346
First received: February 7, 2009
Last updated: May 16, 2016
Last verified: May 2016